Početna stranicaCVM • NYSEAMERICAN
add
CEL-SCI Corp
0,41 $
Poslije radnog vremena:(5,64 %)−0,023
0,39 $
Zatvoreno: 13. sij, 19:40:57 GMT -5 · USD · NYSEAMERICAN · Odricanje od odgovornosti
Preth. zaklj. cijena
0,43 $
Dnevni raspon
0,38 $ - 0,43 $
Godišnji raspon
0,36 $ - 3,08 $
Tržišna kapitalizacija
30,36 mil. USD
Prosječna količina
1,55 mil.
P/E omjer
-
Prinos dividende
-
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | lip 2024.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 1,97 mil. | −19,84 % |
Neto dohodak | −7,52 mil. | 10,17 % |
Neto profitabilnost | — | — |
Zarada po dionici | — | — |
EBITDA | −5,69 mil. | 20,98 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | lip 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 435,78 tis. | −91,55 % |
Ukupna imovina | 24,07 mil. | −25,53 % |
Ukupne obveze | 15,60 mil. | −11,03 % |
Ukupni kapital | 8,47 mil. | — |
Dionice u optjecaju | 61,49 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 2,66 | — |
Povrat imovine | −61,63 % | — |
Povrat kapitala | −70,15 % | — |
Tok novca
Neto promjena novca
| (USD) | lip 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −7,52 mil. | 10,17 % |
Gotovina od poslovanja | −4,58 mil. | 19,19 % |
Gotovina iz ulaganja | −23,47 tis. | 88,08 % |
Gotovina iz financiranja | −322,30 tis. | −133,87 % |
Neto promjena novca | −4,92 mil. | −0,27 % |
Slobodan tok novca | −1,94 mil. | 32,46 % |
Više
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
Osnovano
ožu 1983
Web-lokacija
Zaposlenici
43
